Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients with Inflammatory Bowel Disease
A study for children with an Inammatory Bowel Disease (IBD) such as Crohn's disease or ulcerative colitis
Sponsor: Janssen Research & Development, LLC
Enrolling: Male and Female Patients
IRB Number: AAAQ9637
U.S. Govt. ID: NCT02566889
Contact: Joel Lavine MD: 212-342-2962 / jl3553@cumc.columbia.edu
Additional Study Information: Researchers at Columbia University are conducting a clinical research study of children with inammatory bowel disease (IBD). This study will examine the eectiveness and safety of an investigational medication inchildren with IBD.
This study is closed
Investigator
Do You Qualify?
Has your child been diagnosed with Crohns disease or ulcerative colitis? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Joel Lavine MD
jl3553@cumc.columbia.edu
212-342-2962
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE